Dr. Pecora on RCCA's New Business and Science Approaches

Andrew L. Pecora, MD, FACP, CPE
Published: Friday, Jan 01, 2016

Andrew L. Pecora, MD, FACP, CPE, chief innovations officer, professor, vice president of Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, president, Regional Cancer Care Associates (RCCA), LLC, discusses new business and science approaches RCCA has taken to better provide value-based care to patients.

From a business standpoint, a new molecular lab has been created, Pecora explains. Secondly, a license has been obtained for RCCA to be its own oral dispensing pharmacy. Though this profits cancer centers, Pecora says this will allow for more cost control, lower costs of services, and increase convenience and safety for patients.

The oral dispensing pharmacy allows for the ability to track patients’ compliance to medication as well as adverse events associated with medications. With the creation of the molecular lab, the services are provided below market price, compared with other reference laboratories.

Andrew L. Pecora, MD, FACP, CPE, chief innovations officer, professor, vice president of Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, president, Regional Cancer Care Associates (RCCA), LLC, discusses new business and science approaches RCCA has taken to better provide value-based care to patients.

From a business standpoint, a new molecular lab has been created, Pecora explains. Secondly, a license has been obtained for RCCA to be its own oral dispensing pharmacy. Though this profits cancer centers, Pecora says this will allow for more cost control, lower costs of services, and increase convenience and safety for patients.

The oral dispensing pharmacy allows for the ability to track patients’ compliance to medication as well as adverse events associated with medications. With the creation of the molecular lab, the services are provided below market price, compared with other reference laboratories.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x